This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41435-024-00294-3/MediaObjects/41435_2024_294_Fig1_HTML.png)
References
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, et al. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology. 2022;11:2096363. https://doi.org/10.1080/2162402X.2022.2096363.
Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;164:114954. https://doi.org/10.1016/j.biopha.2023.114954.
Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15:e257–67. https://doi.org/10.1016/S1470-2045(13)70585-0.
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3:911–26. https://doi.org/10.1038/s43018-022-00418-6.
Naulaerts S, Datsi A, Borras DM, Antoranz Martinez A, Messiaen J, Vanmeerbeek I, et al. Multiomics and spatial mapping characterizes human CD8+T cell states in cancer. Sci Transl Med. 2023;15:eadd1016. https://doi.org/10.1126/scitranslmed.add1016.
Borràs DM, Verbandt S, Ausserhofer M, Sturm G, Lim J, Verge GA, et al. Single cell dynamics of tumor specificity vs bystander activity in CD8+T cells define the diverse immune landscapes in colorectal cancer. Cell Discov. 2023;9:114. https://doi.org/10.1038/s41421-023-00605-4.
Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8:450. https://doi.org/10.1038/s41392-023-01674-3.
Fu C, Ma T, Zhou L, Mi Q-S, Jiang A. Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities. Immunol Invest. 2022;51:2133–58. https://doi.org/10.1080/08820139.2022.2109486.
Chen MY, Zhang F, Goedegebuure SP, Gillanders WE. Dendritic cell subsets and implications for cancer immunotherapy. Front Immunol. 2024;15:1393451. https://doi.org/10.3389/fimmu.2024.1393451.
Mahaki H, Ravari H, Kazemzadeh G, Lotfian E, Daddost RA, Avan A, et al. Pro-inflammatory responses after peptide-based cancer immunotherapy. Heliyon. 2024;10:e32249. https://doi.org/10.1016/j.heliyon.2024.e32249.
Fujioka Y, Ueki H, A Ruhan, Sasajima A, Tomono T, Ukawa M, et al. The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine. Int J Mol Sci. 2024;25:5997. https://doi.org/10.3390/ijms25115997.
Sprooten J, Vanmeerbeek I, Datsi A, Govaerts J, Naulaerts S, Laureano RS, et al. Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+T cells. Cell Rep Med. 2024;5:101377. https://doi.org/10.1016/j.xcrm.2023.101377.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, et al. A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma. Nat Med. 2024;30:1667–79. https://doi.org/10.1038/s41591-024-02978-9.
Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano RS, Govaerts J, Trotta R, et al. Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy. Sci Adv. 2024;10:eadm8660. https://doi.org/10.1126/sciadv.adm8660.
Laureano RS, Vanmeerbeek I, Sprooten J, Govaerts J, Naulaerts S, Garg AD. The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy. Immunol Rev. 2024;321:71–93. https://doi.org/10.1111/imr.13287.
Acknowledgements
ADG is supported by Research Foundation Flanders (FWO) (Fundamental Research Grant, G0B4620N; Excellence of Science/EOS grant, 30837538, for ‘DECODE’ consortium; Strategic Basic Research or SBO grant, S000523N), KU Leuven (C1 grant, C14/24/122; and C3 grants, C3/23/067, C3/21/037, C3/22/022), Come Up Against Cancer or Kom op Tegen Kanker (KOTK/2018/11509/1 and KOTK/2019/11955/1), VLIR-UOS (iBOF grant, iBOF/21/048, for ‘MIMICRY’ consortium), Olivia Hendrickx Research Foundation (OHRF), and European Union (EU) Mission Cancer grant for the GLIOMATCH consortium (Project no. 101136670). JS was funded by Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society through the Emmanuel van der Schueren (EvDS) PhD fellowship (projectID: 12699) and KU Leuven's Postdoctoral Mandate (PDM) fellowship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
ADG received consulting/advisory/lecture honoraria or R&D contracts from Boehringer Ingelheim (Germany), Miltenyi Biotec (Germany), Novigenix (Switzerland), Sotio (Czech Republic) and IsoPlexis (USA). The other authors have no conflicts of interest to declare.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sprooten, J., Garg, A.D. Next-generation DC vaccines with an immunogenic trajectory against cancer: therapeutic opportunities vs. resistance mechanisms. Genes Immun (2024). https://doi.org/10.1038/s41435-024-00294-3
Published:
DOI: https://doi.org/10.1038/s41435-024-00294-3